3 Asian Stocks Estimated To Be Trading At Up To 50% Discount

Amidst heightened global market volatility and concerns over AI-related investments, the Asian markets have been experiencing a shift towards more value-oriented segments. Investors are increasingly focusing on stocks that may be trading at significant discounts, presenting potential opportunities for those looking to capitalize on undervalued assets. Identifying stocks with strong fundamentals and resilience in volatile conditions can be key to navigating the current economic landscape.

Top 10 Undervalued Stocks Based On Cash Flows In Asia

Name	Current Price	Fair Value (Est)	Discount (Est)
P.S.P. Specialties (SET:PSP)	THB7.40	THB14.57	49.2%
PAL GROUP Holdings (TSE:2726)	¥1459.00	¥2911.72	49.9%
Nissui (TSE:1332)	¥1109.50	¥2165.31	48.8%
Kumagai GumiLtd (TSE:1861)	¥1217.00	¥2410.08	49.5%
Kona ILtd (KOSDAQ:A052400)	₩34800.00	₩69484.98	49.9%
Jason Furniture (Hangzhou)Ltd (SHSE:603816)	CN¥24.30	CN¥48.39	49.8%
ENN Energy Holdings (SEHK:2688)	HK$50.15	HK$97.07	48.3%
China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999)	CN¥26.26	CN¥52.47	50%
China Coal Energy (SEHK:1898)	HK$10.37	HK$20.16	48.6%
Apex Mining (PSE:APX)	₱16.94	₱33.35	49.2%

Click here to see the full list of 175 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Apex Mining (PSE:APX)

Overview: Apex Mining Co., Inc. operates in the Philippines, focusing on mining and processing metals and minerals, with a market capitalization of approximately ₱97.57 billion.

Operations: Apex Mining Co., Inc. generates revenue through its activities in mining, milling, concentrating, converting, smelting, treating, preparing for market, manufacturing, buying, selling, and exchanging metals and minerals within the Philippines.

Estimated Discount To Fair Value: 49.2%

Apex Mining's recent financial performance highlights its potential as an undervalued stock based on cash flows. With earnings growing significantly, the company trades at ₱16.94, well below its estimated future cash flow value of ₱33.35. Despite a volatile share price and a dividend not fully covered by free cash flows, Apex is expected to outperform the Philippine market with forecasted annual profit growth of 27% and revenue growth of 26.6%.

• The growth report we've compiled suggests that Apex Mining's future prospects could be on the up.
• Click to explore a detailed breakdown of our findings in Apex Mining's balance sheet health report.

P.S.P. Specialties (SET:PSP)

Overview: P.S.P. Specialties Public Company Limited, with a market cap of THB9.94 billion, manufactures and sells lubricant and grease oils in Thailand through its subsidiaries.

Operations: The company generates revenue from two main segments: Sales, contributing THB13.34 billion, and Services, adding THB678 million.

Estimated Discount To Fair Value: 49.2%

P.S.P. Specialties demonstrates potential as an undervalued stock based on cash flows, trading at THB 7.4, significantly below its estimated future cash flow value of THB 14.57. Despite a volatile share price and an unstable dividend track record, the company has shown robust earnings growth of 38.8% over the past year and is expected to outperform the Thai market with forecasted annual profit growth of 12.4% and revenue growth of 9.1%.

• Our earnings growth report unveils the potential for significant increases in P.S.P. Specialties' future results.
• Get an in-depth perspective on P.S.P. Specialties' balance sheet by reading our health report here.

China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999)

Overview: China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. operates in the healthcare sector, focusing on the production and distribution of pharmaceuticals, with a market cap of CN¥42.55 billion.

Operations: The company's revenue is primarily derived from its Pharmaceutical segment, which generated CN¥28.47 billion, and its Medicines, Equipment Wholesale and Retail Industry Segment, which contributed CN¥3.16 billion, with a smaller portion coming from Printing and Packaging at CN¥835.52 million.

Estimated Discount To Fair Value: 50%

China Resources Sanjiu Medical & Pharmaceutical trades at CN¥26.26, significantly below its estimated future cash flow value of CN¥52.47, suggesting potential undervaluation. Despite an unstable dividend track record with recent decreases, the company has shown earnings growth of 17.7% over the past year. However, forecasted annual earnings growth of 10.7% and revenue growth of 5.3% are expected to lag behind the broader Chinese market's performance in these areas.

• According our earnings growth report, there's an indication that China Resources Sanjiu Medical & Pharmaceutical might be ready to expand.
• Click here to discover the nuances of China Resources Sanjiu Medical & Pharmaceutical with our detailed financial health report.

Make It Happen

• Gain an insight into the universe of 175 Undervalued Asian Stocks Based On Cash Flows by clicking here.
• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com